Exthymic Receives Up to $25 Million ARPA-H Award to Advance LITTLESTAR Cell Therapy Manufacturing Device
Exthymic Corporation, a biotechnology company developing technologies designed to expand access to engineered cell therapies, announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to develop a next-generation cell therapy manufacturing device.
The ARPA-H award will support Exthymic’s work on LITTLESTAR, an adaptive manufacturing platform designed to address some of the major challenges that continue to limit the accessibility, scalability and affordability of personalized cell therapies.
Under the Scalable Cell Therapies through Optimized Phenotyping and Enrichment (SCOPE) project, Exthymic can receive up to $25 million over two years to develop and test the LITTLESTAR device. The technology is being designed to enable safer and more reliable production of engineered cell therapies, including chimeric antigen receptor T-cell (CAR-T) therapy, by accounting for differences in individual patients’ cells throughout the manufacturing process.
The company believes the approach could eventually help shift cell therapy manufacturing away from highly centralized production facilities and toward community hospitals and other acute-care settings.
Addressing Patient Variability in Cell Therapy Manufacturing
Cell therapies have emerged as an important area of advanced medicine because they can use a patient’s own cells to create highly personalized treatments. CAR-T therapies, for example, involve collecting a patient’s cells and modifying them outside the body so they can recognize and attack disease-associated targets before being administered back to the patient.
However, the personalized nature of these therapies also creates a major manufacturing challenge.
Cells collected from different patients can vary considerably in their biological characteristics, including their phenotype and behavior during manufacturing. These differences can affect how cells respond to processing, expansion and engineering steps and may ultimately influence whether a manufacturing process produces an acceptable therapeutic product.
Exthymic argues that the cell therapy industry has made substantial progress optimizing manufacturing processes, but that conventional approaches continue to face limitations because they generally depend on standardized processes that may not adequately account for patient-to-patient differences.
Rich Stoner, Chief Executive Officer of Exthymic, said the very characteristic that makes personalized cell therapies powerful also contributes to their manufacturing complexity.
“Using a patient’s own cells is what makes cell therapies powerful. It’s also what makes them so hard to produce,” Stoner said.
He explained that the industry has spent years optimizing production processes but still lacks a comprehensive way to determine why cells from one patient may perform differently from those of another patient.
“The industry has spent a decade optimizing production, but it still can’t tell you what makes one patient’s cells work and another’s fail,” he said. “So it settles for a process it can get approved, and then decides which patients that process will accept.”
According to Stoner, such an approach does not provide a sustainable solution to the challenges of access and commercial scale.
“We won’t solve access or scale commercially that way. Simply put, we’re failing patients,” he added.
LITTLESTAR Designed as an Adaptive Manufacturing Platform
The LITTLESTAR device is being developed around a different approach to cell therapy production.
Rather than relying solely on a fixed manufacturing process, the system is designed to directly measure differences in cell phenotype and respond to those differences throughout the production process.
This adaptive control is intended to allow the manufacturing process to respond to the biological characteristics of an individual patient’s cells as production progresses.
The objective is to produce each final dose in a way that is safe and reliable while reducing the infrastructure traditionally associated with highly controlled cell therapy manufacturing.
According to Exthymic, LITTLESTAR is being designed to enable production without the overhead of a dedicated clean room or quality control laboratory.
If the technology performs as intended, this could have implications for where engineered cell therapies are manufactured.
Today, many personalized cell therapies rely on centralized manufacturing infrastructure and specialized facilities. Such models can introduce logistical challenges, particularly when a patient’s cells must travel from a treatment center to a manufacturing facility and the final product subsequently needs to be returned for administration.
A more distributed manufacturing model could potentially reduce some of these logistical barriers by bringing production closer to the patient.
Exthymic envisions LITTLESTAR supporting production in community hospitals and other acute-care settings, potentially bringing advanced cell therapy capabilities to healthcare facilities that may not currently have access to centralized manufacturing infrastructure.
ARPA-H SCOPE Program Supports High-Risk Innovation
The Exthymic award is being made through ARPA-H’s SCOPE project, which is focused on advancing technologies capable of improving the scalability and accessibility of cell therapies.
ARPA-H was established to pursue ambitious biomedical and health research projects where conventional approaches may not be sufficient to address major healthcare challenges. Its programs are designed to support high-risk, high-reward technologies with the potential to produce significant improvements in health outcomes and healthcare delivery.
John Schiel, ARPA-H Program Manager, said the SCOPE initiative represents the type of research investment the agency was created to pursue.
“SCOPE reflects exactly the kind of high-risk, high-reward biomedical and health research investments ARPA-H was created to make,” Schiel said.
“If successful, it will greatly improve access to these therapies and where patients can receive them,” he added.
The potential impact of the project extends beyond manufacturing efficiency. By addressing the biological variability inherent in personalized cell therapy production, the initiative is intended to explore whether advanced manufacturing technology can help make these therapies available to a larger patient population.
Potential Impact on CAR-T Therapy
One of Exthymic’s planned applications for LITTLESTAR is CAR-T cell therapy, one of the most prominent forms of engineered cellular medicine.
CAR-T therapy involves modifying a patient’s own T cells to express a chimeric antigen receptor capable of recognizing a specific target. After manufacturing and quality testing, the engineered cells are returned to the patient, where they are intended to recognize and attack targeted cells.
CAR-T therapy has demonstrated the potential to produce durable responses in certain cancers, particularly in some hematologic malignancies. However, access to these treatments can be constrained by manufacturing complexity, specialized infrastructure, treatment-center requirements and other logistical considerations.
Exthymic’s approach seeks to address the manufacturing component of that challenge.
By developing an adaptive platform capable of monitoring and responding to cell phenotype throughout production, the company hopes to establish a manufacturing process that is better equipped to handle the inherent variability of patient-derived starting material.
The company is not limiting its plans to a single therapeutic application. As part of the SCOPE project, Exthymic plans to develop multiple therapeutic assets on top of the LITTLESTAR instrument, with CAR-T included among those programs.
Academic Collaboration
Exthymic is working with academic partners as part of the SCOPE project.
The company is collaborating with researchers at the University of California, San Francisco (UCSF) and the Gates Institute at the University of Colorado Anschutz.
These partnerships are expected to contribute academic expertise and research capabilities to the development and testing of the LITTLESTAR technology.
Collaboration between biotechnology companies and academic institutions can be particularly important for emerging cell therapy technologies because development requires expertise spanning cell biology, manufacturing, engineering, process control and clinical translation.
The SCOPE project brings these areas together around a common objective: developing a scalable approach to cell therapy manufacturing that can account for patient-specific biological variability.
Moving Toward Clinical Development
Exthymic plans to advance multiple therapeutic programs using the LITTLESTAR platform, with clinical trials planned for early 2028.
The planned clinical development represents an important future milestone for the technology. Before the platform can potentially become a broadly used manufacturing solution, the company will need to establish that it can consistently produce cell therapy products that meet appropriate safety and quality requirements.
The development program supported by ARPA-H is therefore expected to focus on both the device itself and its application to engineered cellular therapies.
The company’s goal is to establish a manufacturing platform that can reliably accommodate the differences between individual patients while maintaining appropriate production controls.
If successful, the approach could have implications beyond CAR-T therapy and potentially support other engineered cell therapy applications.
Expanding Access to Curative Therapies
For Exthymic, the ultimate objective of the LITTLESTAR program is not simply to develop a new manufacturing instrument. The company views the technology as a potential means of addressing disparities in access to advanced cellular therapies.
Stoner emphasized that patients who could potentially benefit from treatments such as CAR-T are not always located near the specialized facilities required to deliver them.
“Exthymic appreciates ARPA-H’s support and their ongoing mission to bring curative therapies to patients across the United States,” Stoner said.
He pointed to cancer as a continuing national healthcare concern and highlighted the geographic barriers that can prevent patients from reaching centers capable of delivering complex cellular treatments.
“Cancer remains a national concern, and frequently the patients that need access to curative treatments like CAR-T are the farthest away from it,” he said.
Stoner described the LITTLESTAR program as a potential new path for addressing this challenge.
“For the first time in a decade we have a path forward that brings cures to patients that have no hope of getting them with the current ex vivo or in vivo approaches,” he added.
The statement reflects Exthymic’s broader ambition to create a decentralized model for delivering sophisticated cell therapies.
Toward More Distributed Cell Therapy Manufacturing
The ability to manufacture cell therapies closer to where patients receive treatment could potentially change the operational model for personalized medicine.
Traditional cell therapy manufacturing can require specialized facilities, controlled environments, complex logistics and extensive quality-control infrastructure. These requirements can contribute to cost and limit the number of healthcare centers capable of offering advanced cellular treatments.
LITTLESTAR is being developed to address some of these challenges through automation and adaptive process control.
The device’s ability to measure cell phenotype and respond to changes during production is central to Exthymic’s strategy. Rather than treating patient variability as an obstacle that must be controlled outside the manufacturing process, the company is attempting to make that variability an integral part of an adaptive production system.
The resulting approach could potentially make it easier to establish manufacturing capabilities in community hospitals and other acute-care environments.
However, the technology remains under development, and its ability to achieve these objectives will need to be demonstrated through the planned research, testing and eventual clinical development program.
The up to $25 million ARPA-H contract over two years gives Exthymic significant support to advance LITTLESTAR through development and testing under the SCOPE project.
The company plans to develop multiple therapeutic assets using the platform, including CAR-T programs, while working with UCSF and the Gates Institute at the University of Colorado Anschutz.
With clinical trials planned for early 2028, Exthymic is positioning LITTLESTAR as a platform technology that could eventually support a broader generation of engineered cell therapies.
The company also plans to publish its case for the future of distributed cell therapy manufacturing through Exthymic.com and preview the core LITTLESTAR technology at the Meeting on the Mesa in October 2026.
The ARPA-H award marks an important step in Exthymic’s effort to address one of the central challenges facing cell therapy: how to make highly personalized treatments more scalable and accessible without losing the safety and reliability required for advanced medicines.
As engineered cell therapies continue to advance, manufacturing remains one of the most important factors determining how broadly these treatments can reach patients. By combining real-time phenotype measurement with adaptive manufacturing control, Exthymic is seeking to develop an alternative model that could move production closer to the point of care.
If successful, LITTLESTAR could help expand the locations where cell therapies are produced, reduce infrastructure requirements and potentially improve access to treatments such as CAR-T. The next stages of the SCOPE project will determine whether the technology can translate that ambition into a reliable manufacturing platform and, ultimately, support the company’s planned clinical programs.
About Exthymic
Exthymic Corporation is developing a family of cell therapy devices and therapeutic assets to reduce the cost of and increase the access to curative engineered cell therapies like CAR-T cell therapy for patients across the United States. Located in San Diego, California, the company was founded by Rich Stoner, Dan Knudsen, and Kevin Cooksy in 2023. The company is backed by major private investors including Dimension Capital and Khosla Ventures.